Hematology Frontier Archives - Page 27 of 74

The 66th American Society of Hematology (ASH) Annual Meeting was grandly held in San Diego, USA, from December 7th to 10th, 2024

By Mourabit Halima 2024.12.10

The 66th American Society of Hematology (ASH) Annual Meeting was grandly held in San Diego, USA, from December 7th to 10th, 2024. As one of the most influential platforms for scientific communication in hematology, this global event attracted over 25,000 professionals, including clinicians, researchers, and healthcare leaders from more than 100 countries. The conference covered all aspects of malignant and non-malignant hematology, from cutting-edge research to clinical practice and therapeutic innovation, reflecting the latest advancements and future trends in the field.

The 66th American Society of Hematology Annual Meeting (ASH)

By Mourabit Halima 2024.12.10

The 66th American Society of Hematology Annual Meeting (ASH) was grandly held in San Diego, USA, from December 7th to 10th, 2024. This annual event is one of the most influential scientific communication platforms in the field of hematology worldwide. This edition of the ASH Annual Meeting attracted over 25,000 professionals, including clinicians, scientists, researchers, and healthcare decision-makers from more than 100 countries around the globe. The conference covered all aspects of malignant and non-malignant hematology, from basic scientific research to clinical practice, from drug development to therapeutic innovation, reflecting the latest advancements and future trends in the field of hematology.

CTI 2024 | Dr. Ibrahim Yakoub-Agha Discusses the Application of Cellular Immunotherapy in Myelofibrosis

By Mourabit Halima 2024.12.06

From November 14th to 17th, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was grandly held in Hangzhou, China, gathering top experts, scholars, and industry leaders in the fields of cell therapy and immune therapy from around the world. The conference served not only as an international platform for academic exchange but also as an important window to showcase the latest scientific research and promote the development of the field. During the conference, "Hematology Frontier" specially invited Dr. Ibrahim Yakoub-Agha from the Lille University , France, to reveal the unlimited potential and broad prospects of cellular immunotherapy in myelofibrosis.

CTI 2024 | ACTO Chairman Dr. Akihiro Shimosaka: Exosomes Empower Innovative Breakthroughs in Immune Cell Therapy

By Mourabit Halima 2024.12.05

From November 14th to 17th, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was grandly held in Hangzhou, China, gathering top experts, scholars, and industry leaders in the field of global cell therapy and immune therapy. The conference served not only as an international platform for academic exchange but also as an important window to showcase the latest scientific research and promote the development of the field. "Hematology Frontier" specially invited the conference chair and the chairman of the Asian Cellular Therapy Organization (ACTO), Dr. Akihiro Shimosaka, to share his profound insights on immune cell therapy, regenerative medicine, gene therapy, and the application of exosomes.

CTI 2024 | Dr. Leo Luznik Shares Exploration and Prospects of Bone Marrow Infiltrating T Cells in the Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

By Yin, Jiale 2024.12.05

From November 14th to 17th, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was grandly held in Hangzhou, China, gathering top experts, scholars, and industry leaders in the field of global cell therapy and immune therapy. The conference served not only as an international platform for academic exchange but also as an important window to showcase the latest scientific research and promote the development of the field. During the conference, "Hematology Frontier" specially invited Dr. Leo Luznik from Baylor College of Medicine,USA to share the latest progress of Bone Marrow Infiltrating T Cells (MITs) in the treatment of relapse after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). He revealed the potential and challenges of MITs in treating relapse after HSCT and looked forward to the future development direction of the field.

CTI 2024 | Dr. Marion Subklewe Reveals How AdCAR-T Cells Dualistically Enhance the Safety and Precision of AML Treatment

By Lisa Cui 2024.12.05

From November 14th to 17th, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was grandly held in Hangzhou, China, gathering top experts, scholars, and industry leaders in the field of global cell therapy and immune therapy. The conference served not only as an international platform for academic exchange but also as an important window to showcase the latest scientific research and promote the development of the field. During the conference, "Hematology Frontier" specially invited Dr. Marion Subklewe from the LMU University Hospital , Germany, to share with us the principles, advantages of AdCAR-T cell technology, and the future optimization direction of AML treatment.

CTI 2024 | IACH Chairman Dr. Mohamad Mohty: Updates on the Latest Treatment Advances in GVHD

By Mourabit Halima 2024.12.05

From November 14th to 17th, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was grandly held in Hangzhou, China, gathering top experts, scholars, and industry leaders in the field of global cell therapy and immune therapy. The conference served not only as an international platform for academic exchange but also as an important window to showcase the latest scientific research and promote the development of the field. During this conference, "Hematology Frontier" specially invited the conference chair and the chairman of the International Academy for Clinical Hematology (IACH), Dr. Mohamad Mohty from Sorbonne University , France, to share his insights on the latest treatment advances in Graft-Versus-Host Disease (GVHD), aiming to provide valuable insights for clinicians and researchers and to explore the future direction of GVHD treatment.

ASH 2024 | Dr. He Huang’s Team Secures 8 Oral Presentations, Showcasing Chinese Excellence on the Global Stage

By Yin, Jiale 2024.12.04

The highly anticipated 66th Annual Meeting of the American Society of Hematology (ASH) will take place in San Diego, USA, from December 7 to 10, 2024. Renowned as one of the largest and most comprehensive international academic events in hematology, the ASH Annual Meeting serves as a premier platform for advancing the frontiers of the discipline. This global gathering attracts thousands of experts and scholars who come together to exchange cutting-edge research and breakthroughs in the field.

CTI 2024 | Professor Li Tang: Promising Horizons for CAR-T and mRNA Gene Therapy

By Mourabit Halima 2024.12.04

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) took place in Hangzhou, China. This global event brought together leading experts, scholars, and industry pioneers in cellular and immune therapies, serving as both an academic platform and a showcase for the latest research breakthroughs. During the conference, Hematology Frontier launched the special column “Professor, Please Answer,” featuring on-the-spot interviews with prominent professors to capture their insights and visions for the future of the field. In this edition, we share the inspiring perspectives of Professor Li Tang from École Polytechnique Fédérale de Lausanne (EPFL), Switzerland.

CTI 2024丨Prof. Xi Zhang: New Developments and Challenges in Chronic Graft-Versus-Host Disease

By Mourabit Halima 2024.12.03

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) took place in Hangzhou, China, bringing together global leaders in cellular and immune therapies. This prestigious event served as a platform for academic exchange and a showcase for cutting-edge research in the field. During the conference, Prof. Xi Zhang from the Department of Hematology at Xinqiao Hospital , Army Medical University shared key insights on chronic graft-versus-host disease (cGVHD).